Experimental therapy for Hodgkin's lymphoma patients;Experimentelle therapie des Hodgkin-lymphoms

Onkologe

Volumn 16, Issue 1, 2010, Pages 48-54

  Boll B ^a,b   Borchmann, P ^a,b   Engert, A ^a,b  

^a German Hodgkin Study Group   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

H RS cell; Immunotherapy; Relapsed hodgkin's lymphoma; Small molecular substances; Targeted therapy

Indexed keywords

ALEMTUZUMAB; APOLIZUMAB; CD16 ANTIGEN; CD20 ANTIBODY; CD64 ANTIGEN; DACLIZUMAB; FERRITIN; GALIXIMAB; HCD 122; IMMUNOMODULATING AGENT; IMMUNOTOXIN; IODINE 131; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MDX 1401; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MDX 060; OFATUMOMAB; PSEUDOMONAS EXOTOXIN; RADIOIMMUNOCONJUGATE I 131; RICIN A; RITUXIMAB; SAPORIN; SGN 30; SGN 35; SGN 40; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY; XMAB 2513; YTTRIUM 90;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER STAGING; CELL THERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG ACTIVITY; EXPERIMENTAL THERAPY; HODGKIN DISEASE; HUMAN; RADIOIMMUNOTHERAPY;

EID: 77951125354     PISSN: 09478965     EISSN: 14330415     Source Type: Journal    
DOI: 10.1007/s00761-009-1765-2     Document Type: Article

References (31)

1. Fuchs M, Diehl V, Re D (2006) Current strategies and new approaches in the treatment of Hodgkin's lymphoma. Pathobiology 73:126-140
2. Kuppers R (2009) The biology of Hodgkin's lymphoma. Nat Rev Cancer 9:15-27
3. Boll B, Hansen H, Heuck F et al (2005) The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis. Blood 106:1839-1842
4. Borchmann P, Treml JF, Hansen H et al (2003) The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood 102:3737-3742
5. Ansell SM, Horwitz SM, Engert A et al (2007) Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 25:2764-2769
6. Forero-Torres A, Leonard JP, Younes A et al (2009) A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 146:171-179
7. Cardarelli PM, Moldovan-Loomis MC, Preston B et al (2009) In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma. Clin Cancer Res 15:3376-3383
8. Diehl V, Sextro M, Franklin J et al (1999) Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 17:776-783
9. Schulz H, Rehwald U, Morschhauser F et al (2008) Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 111:109-111
10. Ekstrand BC, Lucas JB, Horwitz SM et al (2003) Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 101:4285-4289
11. Oki Y, Pro B, Fayad LE et al (2008) Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 112:831-836
12. Agarwal B, Naresh KN (2003) Re: Doussis-Anagnostopoulou et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed- Sternberg cells in Hodgkin's disease. J Pathol 2002; 197:677-683.
13. J Pathol 201:334-355
14. Reiners KS, Gossmann A, von Strandmann EP et al (2009) Effects of the anti-VEGF monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed Hodgkin lymphoma. J Immunother 32:508-512
15. Vooijs WC, Otten HG, van Vliet M et al (1997) B7-1 (CD80) as target for immunotoxin therapy for Hodgkin's disease. Br J Cancer 76:1163-1169
16. Borchmann P, Schnell R, Engert A (2005) Immunotherapy of Hodgkin's lymphoma. Eur J Haematol Suppl 159-165
17. Engert A, Diehl V, Schnell R et al (1997) A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood 89:403-410
18. Falini B, Bolognesi A, Flenghi L et al (1992) Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 339:1195-1196
19. Kreitman RJ, Squires DR, Stetler-Stevenson M et al (2005) Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 23:6719-6729
20. Senter PD (2009) Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 13:235-244
21. Younes A, Forero-Torres A, Bartlett NL et al (2008) Multiple complete responses in a phase 1 dose escalation study of the antibody drug conjugate SGN 35 in patients with relapsed or refractory CD 30 positive lymphomas. Blood 112:1006
22. Klimm B, Schnell R, Diehl V et al (2005) Current treatment and immunotherapy of Hodgkin's lymphoma. Haematologica 90:1680-1692
23. Schnell R, Dietlein M, Staak JO et al (2005) Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol 23:4669-4678
24. Hartmann F, Renner C, Jung W et al (1997) Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood 89:2042-2047
25. Hartmann F, Renner C, Jung W et al (2001) Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. Clin Cancer Res 7:1873-1881
26. Borchmann P, Schnell R, Fuss I et al (2002) Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood 100:3101-3107
27. Bollard CM, Aguilar L, Straathof KC et al (2004) Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med 200:1623-1633
28. Boll B, Borchmann P, Topp MS et al (2009) Lenalidomide in patients with refractory or multiple relapsed Hodgkin's Lymphoma. Br J Haematol Accepted
29. Hartlapp I, Pallasch C, Weibert G et al (2009) Depsipeptide induces cell death in Hodgkin lymphomaderived cell lines. Leuk Res 33:929-936
30. Wildes TM, Bartlett NL (2009) Drug development for recurrent and refractory classical Hodgkin lymphoma. Leuk Lymphoma 50:529-540
31. Boll B, Eltaib F, Reiners KS et al (2009) Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity. Clin Cancer Res 15:5108-5116